OncoMatch/Clinical Trials/NCT07143812
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
Is NCT07143812 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies MSC11FCD for glioblastoma (gbm).
Treatment: MSC11FCD — This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients with newly diagnosed glioblastoma. The investigational product is administered intratumorally following surgical resection. This study aims to explore whether MSC11FCD can provide a targeted, localized treatment option during the postsurgical period, potentially addressing residual tumor cells and reducing early recurrence.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Prior therapy
Must have received: standard therapy for glioblastoma
after receiving standard therapy for glioblastoma
Cannot have received: immunotherapy
Patients who have not received any other types of immunotherapy
Cannot have received: Gliadel wafer (Gliadel wafer)
Patients who received Gliadel wafer implantation during surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07143812 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy, Gliadel wafer disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages